Insider Ivan Hyep Files to Sell Bicara Therapeutics Shares

TL;DR

**Insider Hyep is selling Bicara Therapeutics shares, watch out for potential stock dip.**

AI Summary

Ivan Hyep, a reporting person, has filed a Form 144 indicating a proposed sale of securities in Bicara Therapeutics Inc. (CIK: 0002023658). This filing, dated March 23, 2026, signals that an insider intends to sell shares, which could be interpreted by investors as a lack of confidence in the company's future prospects. For current or prospective shareholders, this matters because significant insider selling can sometimes precede a decline in stock price, suggesting that those with the most intimate knowledge of the company believe the stock may be overvalued or that better opportunities exist elsewhere.

Why It Matters

This filing indicates a potential sale of shares by an insider, Ivan Hyep, which could signal a lack of confidence in Bicara Therapeutics Inc. and potentially impact investor sentiment and the stock price.

Risk Assessment

Risk Level: medium — Insider selling can sometimes indicate a lack of confidence in the company's future, posing a moderate risk to current and prospective investors.

Analyst Insight

A smart investor would monitor Bicara Therapeutics Inc.'s stock performance closely and investigate the reasons behind Ivan Hyep's proposed sale, considering if this insider action reflects broader concerns about the company's future or if it's merely for personal liquidity.

Key Players & Entities

• Hyep Ivan (person) — Reporting person proposing to sell securities
• Bicara Therapeutics Inc. (company) — The company whose securities are being proposed for sale
• 0002034668 (person) — CIK for Hyep Ivan
• 0002023658 (company) — CIK for Bicara Therapeutics Inc.
• March 23, 2026 (date) — Filing date of the Form 144

Forward-Looking Statements

• Bicara Therapeutics Inc.'s stock price may experience downward pressure. (Bicara Therapeutics Inc.) — medium confidence, target: Within 3 months of filing date

FAQ

Filing Documents

• primary_doc.html (144)
• primary_doc.xml (144) — 5KB
• 0001969223-26-000383.txt ( ) — 6KB

From the Filing

Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933 FORM 144 144: Filer Information Is this a LIVE or TEST Filing? LIVE TEST Submission Contact Information Name Phone E-Mail Address 144: Issuer Information Name of Issuer Bicara Therapeutics Inc. Address of Issuer 116 HUNTINGTON AVENUE SUITE 703 BOSTON MASSACHUSETTS 02116 Phone 617-468-4219 Name of Person for Whose Account the Securities are To Be Sold Hyep Ivan See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice. Relationship to Issuer Officer 144: Securities Information Title of the Class of Securities To Be Sold Name and Address of the Broker Number of Shares or Other Units To Be Sold Aggregate Market Value Number of Shares or Other Units Outstanding Approximate Date of Sale Name the Securities Exchange Common UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York � NY � 10010 9200 171120.00 54781950 03/23/2026 NASDAQ Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor: 144: Securities To Be Sold Title of the Class Date you Acquired Nature of Acquisition Transaction Name of Person from Whom Acquired Is this a Gift? Date Donor Acquired Amount of Securities Acquired Date of Payment Nature of Payment * Common 03/23/2026 Exercise of stock options Issuer 9200 03/23/2026 Cash * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid. Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold. 144: Securities Sold During The Past 3 Months Name and Address of Seller Title of Securities Sold Date of Sale Amount of Securities Sold Gross Proceeds Ivan Hyep 116 HUNTINGTON AVENUE SUITE 703 Boston � MA � 02116 Common 01/22/2026 1882 34162.44 Ivan Hyep 116 HUNTINGTON AVENUE SUITE 703 Boston � MA � 02116 Common 03/03/2026 13555 246909.75 Ivan Hyep 116 HUNTINGTON AVENUE SUITE 703 Boston � MA � 02116 Common 03/04/2026 2963 54061.71 144: Remarks and Signature Remarks Date of Notice 03/23/2026 Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1 02/13/2025 ATTENTION: The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. Signature /s/ UBS Financial Services Inc., as attorney-in-fact for Ivan Hyep ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

View Full Filing

View this 144 filing on SEC EDGAR